Facial Aging
Conditions
Interventions
experimental side:Radio frequency microneedle plus fat derivative application
control side:Nil
Sponsors
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
Eligibility
Sex/Gender
All
Age
20 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Three age groups: 20 to 40 years old, 45 to 55 years old, 60 to 65 years old; 2. Gender: 2 men and 2 women in each age group; 3. BMI is within the range of 18.5-23.9 (including boundary values); 4. Sign the informed consent form, agree to participate in the study and be able to cooperate with the worker who completes the follow-up.
Exclusion criteria
Exclusion criteria: 1. Those who have undergone liposuction in the area waiting for liposuction under the abdomen or buttocks; 2. History of smoking (more than 1 pack per day), history of drug, alcohol or drug abuse; 3. Women who are pregnant, within one year after delivery, breastfeeding, and women who plan to become pregnant within one year; 4. There are significant scars, wounds, severe acne, etc. on the face that affect the evaluation of facial efficacy; 5. Drugs (for example, aspirin, non-steroidal anti-inflammatory drugs, clopidogrel, warfarin, etc.) that can prolong the clotting time have been used within 2 weeks before screening. For menstrual period subjects, treatment can be postponed as needed. Avoid the menstrual period; 6. Subjects who have used topical drugs (such as glucocorticoids, tretinoin ointment) on the upper face within 4 weeks before screening, or are expected to use these drugs on the upper face during the study (until 24 weeks after the completion of the injection treatment) By; 7. Subjects who have received or plan to receive eyebrow lift, laser skin resurfacing, skin rejuvenation, intense pulsed light, radiofrequency, abrasion, chemical peeling, or other ablation or non-ablation surgery on the upper face during the study period within 6 months before screening By; 8. Subjects who received hyaluronic acid injections on the upper face within the 12 months before screening or planned to be injected during the study period; 9. Obviously abnormal in laboratory examination before screening 10. Participate in any other clinical trials within 3 months before screening; 11. There are infectious diseases before screening, such as: syphilis, AIDS, hepatitis B, past or current subjects have severe cardiovascular, gastrointestinal, respiratory, endocrine, nephritis, liver disease patients or liver that may adversely affect this clinical trial Insufficiency, history of malignant tumors (except for thyroid cancer and cervical cancer in situ, which have been diagnosed as malignant tumors in the past 5 years, are stable and have received appropriate treatment or resection), or central nervous system disorders and mental disorders cannot fully understand and Cooperative subjects have any other comorbid diseases that the researcher believes may interfere with the evaluation of the research, or the researcher believes that participating in the research may cause the subjects to face greater risks; 12. There are situations in which other investigators have assessed that they are not suitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effect; | — |
Countries
China
Contacts
Public ContactXie Yun
Shanghai Ninth People's Hospital
Outcome results
None listed